Lydia Montes
Amiens, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Teclistamab in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis of the French RetrosTECtive Cohort.
Journal: EJHaem
Published: October 16, 2025
POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia.
Journal: Blood advances
Published: July 14, 2025
POD24 is a Novel Determinant of Prognosis in Patients with Waldenström Macroglobulinemia.
Journal: Blood advances
Published: July 14, 2025
The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: July 03, 2025
Waldenström's macroglobulinemia: The LYSA pragmatic guidelines.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 28, 2025
Tandem combination of ASCT and CAR T-cell therapy in highly refractory CNS lymphomas.
Journal: British journal of haematology
Published: February 05, 2025
Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program.
Journal: Haematologica
Published: July 20, 2024
Teclistamab for relapsed refractory multiple myeloma patients on dialysis.
Journal: British journal of haematology
Published: July 15, 2024
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.
Journal: Nature medicine
Published: April 18, 2024
Twice-weekly induction with ixazomib-lenalidomide-dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant-eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014-03.
Journal: British journal of haematology
Published: January 05, 2024
Last Updated: 09/26/2026